Cybin Announces Completion of Previously Announced Share Consolidation Page 1

Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a pioneering clinical-stage neuropsychiatric company committed to revolutionizing mental health care by developing novel and innovative next-generation treatment options, is pleased to announce that it has filed articles of incorporation to consolidate the Company’s issued and outstanding common stock (the “Ordinary shares”) on the basis of one new ordinary share for every 38 existing ordinary shares (the “Consolidation”). The Consolidation is effective immediately and trading in the Ordinary Shares reflecting the Consolidation will commence at the open of business today.

As a result of the Consolidation, the 759,692,495 issued and outstanding common shares prior to the Consolidation have been reduced to approximately 19,991,907 common shares, subject to adjustment for treatment of fractional common shares. The percentage ownership of each shareholder in the Company and the proportionate voting rights will remain unchanged following the Consolidation, except for minor changes and adjustments resulting from the treatment of fractional common shares.

The exercise price and the number of ordinary shares issuable upon exercise of the Company’s outstanding warrants and options on ordinary shares have been adjusted in accordance with the consolidation.

About Cybin

Cybin is a clinical-stage, breakthrough neuropsychiatric company focused on developing safe and effective next-generation therapies to address the significant unmet need for novel and innovative treatment options for people living with mental illness.

Cybin’s mission to revolutionize mental health care is supported by a network of world-class partners and internationally recognized scientists focused on developing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens. Cybin is currently developing CYB003, a proprietary deuterated psilocin program for the treatment of Major Depressive Disorder and CYB004, a proprietary deuterated dimethyltryptamine program for Generalized Anxiety Disorder and has a research pipeline of experimental psychedelic compounds.